Back to top

Top Ranked Momentum Stocks to Buy for November 9th

Read MoreHide Full Article

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 9th:

Vericel Corporation (VCEL - Free Report) : This cloud-based platform solutions provider has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.2% over the last 60 days.

Vericel's shares gained 23.4% over the last one month in contrast to the S&P 500’s decrease of 2.6%. The company possesses a Momentum Score of A.

Pacira Pharmaceuticals, Inc. (PCRX - Free Report) : This specialty pharmaceutical company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings jumping 46.3% over the last 60 days.

Pacira Pharmaceuticals’ shares gained 7.5% over the last one month. The company possesses a Momentum Score of A.

NeoGenomics, Inc. (NEO - Free Report) : This operator of a network of cancer-focused genetic testing laboratories has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 20% over the last 60 days.

NeoGenomics’ shares gained 25% over the last one month. The company possesses a Momentum Score of A.

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Vericel Corporation (VCEL) - free report >>

Pacira Pharmaceuticals, Inc. (PCRX) - free report >>

NeoGenomics, Inc. (NEO) - free report >>

More from Zacks Zacks #1 Rank Additions

You May Like

Published in